Lymphocyte Xanthine Oxidoreductase: Activity vs Extraarticular Manifestations in Rheumatoid Arthritis

Study Objective: To study lymphocyte lysates for the dependence of the activity of xanthine oxidoreductase (XOR) complex: xanthine oxidase (XO) and xanthine dehydrogenase (XDG) — on the presence of extraarticular (systemic) manifestations (EAM) in patients with rheumatoid arthritis (RA).

Study Design: Comparative study.

Material and Methods. The study included 77 patients with verified RA (study group) and 35 apparently healthy subjects (control group). Lymphocytes were isolated using А. Böyum method in Lymphosep with a density gradient of 1.077–1.079 g/mL. Ferment activity was measured with kinetic methods and expressed in nM/min/mL equivalent to 10 7 cells per 1 mL. Study Results. XO reference range is 14.11–31.33 nM/min/mL; that of XDG — 18.62–39.64 nM/min/mL. For RA patients as a whole and  patients with and without EAMs, lymphocytes demonstrated a significant reduction in the activity of both ferments vs controls (р < 0.001); in RA patients with EAMs, the XO and XDG activity was even lower (р < 0.001). Spearman correlation analysis identified the dependence of XO and XDG activity on the presence of EAMs: direct moderate correlations for XO (ρ = 0.6; p < 0.001) and XDG (ρ = 0.499; p = 0.000041). There is a strong direct correlation between XO and XDG activity, the intensity of which was higher where RA was associated with EAMs: (ρ = 0.72; p = 0.025) and (ρ = 0.87, p = 0.004) for RA only with articular involvement and for RA with EAMs, respectively.

Conclusion. In lymphocytes of patients with RA, we found some changes in the XOR enzyme profile, the intensity of which depends on the presence of EAMs in the clinical presentation of the disease. Where XO activity is below 10.86 nM/min/mL and/or with XDG activity below 14.31 nM/min/mL, it isassumed that RA patients have EAMs. It is then recommended that the patient undergoes a comprehensive examination for early EAM identification and therapy adjustment.

1. Stojanovic A., Veselinovic M., Draginic N. et al. The influence of menopause and inflammation on redox status and bone mineral density in patients with rheumatoid arthritis. Oxid. Med. Cell Longev. 2021; 9458587. DOI: 10.1155/2021/9458587

2. Marcucci E., Bartoloni E., Alunno A. et al. Extra-articular rheumatoid arthritis. Reumatismo. 2018; 70(4): 212–24. DOI: 10.4081/reumatismo.2018.1106

3. Моисеев С.В., Новиков П.И., Чеботарёва Н.В. и др. Внесуставные (системные) проявления ревматоидного артрита. Клиническая фармакология и терапия. 2020; 29(1): 53–60 [Moiseev S.V., Novikov P.I., Chebotareva N.V. et al. Extraarticular (systemic) manifestations of rheumatoid arthritis. Clinical Pharmacology and Therapy. 2020; 29(1): 53–60. (in Russian)]. DOI: 10.32756/0869-5490-2020-1-53-60

4. Giles J.T. Extra-articular manifestations and comorbidity in rheumatoid arthritis: potential impact of pre-rheumatoid arthritis prevention. Clin. Ther. 2019; 41(7): 1246–55. DOI: 10.1016/j.clinthera.2019.04.018

5. Figus F.A., Piga M., Azzolin I. et al. Rheumatoid arthritis: extra articular manifestations and comorbidities. Autoimmun. Rev. 2021; 20(4): 102776. DOI: 10.1016/j.autrev.2021.102776

6. Ferreira H.B., Melo T., Paiva A. et al. Insights in the role of lipids, oxidative stress and inflammation in rheumatoid arthritis unveiled by new trends in lipidomic investigations. Antioxidants (Basel). 2021; 10(1): 45. DOI: 10.3390/antiox10010045

7. da Fonseca L.J.S., Nunes-Souza V., Goulart M.O.F. et al. Oxidative stress in rheumatoid arthritis: what the future might hold regarding novel biomarkers and add-on therapies. Oxid. Med. Cell Longev. 2019; 7536805. DOI: 10.1155/2019/7536805

8. Bala A., Mondal C., Haldar P.K. et al. Oxidative stress in inflammatory cells of patient with rheumatoid arthritis: clinical efficacy of dietary antioxidants. Inflammopharmacology. 2017; 25(6): 595–607. DOI: 10.1007/s10787-017-0397-1

9. Belikov A.V., Schraven B., Simeoni L. T cells and reactive oxygen species. J. Biomed. Sci. 2015; 22: 85. DOI: 10.1186/s12929-015-0194-3

10. Furuhashi M. New insights into purine metabolism in metabolic diseases: role of xanthine oxidoreductase activity. Am. J. Physiol. Endocrinol. Metab. 2020; 319(5): E827–34. DOI: 10.1152/ajpendo.00378.2020

11. Battelli M.G., Bortolotti M., Polito L. et al. The role of xanthine oxidoreductase and uric acid in metabolic syndrome. Biochim. Biophys. Acta Mol. Basis Dis. 2018; 1864(8): 2557–65. DOI: 10.1016/j.bbadis.2018.05.003

12. Polito L., Bortolotti M., Battelli M.G. et al. Xanthine oxidoreductase: a leading actor in cardiovascular disease drama. Redox. Biol. 2021, 48: 102195. DOI: 10.1016/j.redox.2021.102195

13. Зборовская И.А., Бедина С.А., Трофименко А.С. и др. Влияние обезболивающих препаратов на активность ферментов пури нового метаболизма в плазме крови и лимфоцитах у больных ревматоидным артритом. Российский журнал боли. 2018; 3(57): 47–53. [Zborovskaya I.A., Bedina S.A., Trofimenko A.S. et al. Influence of analgetics on plasma and lymphocytic activity of the purine metabolism enzymes in rheumatoid arthritis patients. Russian Journal of Pain. 2018; 3(57): 47–53. (in Russian)]. DOI: 10.25731/RASP.2018.03.018

14. Дягина Е.Г. Активность КО в сыворотке крови у больных с хирургическими заболеваниями печени, желчевыводящих путей и другими заболеваниями. Лабораторное дело. 1973; 11: 647–49. [Dyagina E.G. XO activity in serum of patients with surgical hepatic and bile conditions and other diseases. Laboratornoe Delo. 1973; 11: 647–49. (in Russian)]

15. Devenyi Z.J., Orchard J.L., Powers R.E. Xanthine oxidase activity in mouse pancreas: effects of caerulein-induced acute pancreatitis. Biochem. Biophys. Res. Commun. 1987; 149(3): 841–5. DOI: 10.1016/0006-291x(87)90484-0

16. Бедина С.А., Трофименко А.С., Мозговая Е.Э. и др. Активность ферментов прооксидантной и антиоксидантной систем в плазме крови больных ревматоидным артритом. Якутский медицинский журнал. 2020; 2(70): 28–30. [Bedina S.A., Trofimenko A.S., Mozgovaya E.E. et al. Activity of prooxidant and antioxidant systems enzymes in plasma of rheumatoid arthritis patients. Yakut Medical Journal. 2020; 2(70): 28–30. (in Russian)]. DOI: 10.25789/YMJ.2020.70.08

17. Мартемьянов В.Ф., Галаева О.Ю., Бедина С.А. и др. Энзимы пури нового метаболизма в клетках крови больных ревматоидным артритом в процессе эволюции болезни. Доктор.Ру. 2012; 2(70): 38–43. [Martemyanov V.F., Galaeva O.Yu., Bedina S.A. et al. Rheumatoid arthritis: purine metabolism enzymes in blood cells and disease evolution. Doctor.Ru. 2012; 2(70): 38–43. (in Russian)]

18. Mateen S., Moin S., Khan A.Q. et al. Increased reactive oxygen species formation and oxidative stress in rheumatoid arthritis. PLOS One. 2016; 11(4): e0152925. DOI: 10.1371/journal.pone.0152925